MILLER MICHAEL PATRICK
Known title: DirectorCIK: 0001236514
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
RIGL: No Recent Company-Specific News Identified. Recent news coverage for Rigel Pharmaceuticals focuses on a different company, Arvinas, rather than RIGL-specific developments. There are no new announcements or events in the provided data that directly impact RIGL's stock performance. The current technical indicators show the stock trading near its support level, but without specific news catalysts, market attention remains limited to broader sector trends.
Transaction History
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2026 | View on chart |
| RIGL | ▲ Buy | Grant | 5,750 | $0 | 5/15/2026 | View on chart |
| PBYI | ▼ Sell | Open Market | 20,000 | $97K | 11/11/2025 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/11/2025 | View on chart |
| PBYI | ▼ Sell | Open Market | 23,358 | $81K | 8/12/2024 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/18/2024 | View on chart |
| PBYI | ▼ Sell | Open Market | 25,000 | $71K | 11/7/2023 | View on chart |
| PBYI | ▼ Sell | Open Market | 13,500 | $47K | 6/13/2023 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/13/2023 | View on chart |
| PBYI | ▼ Sell | Open Market | 25,000 | $89K | 8/9/2022 | View on chart |
| PBYI | ▲ Buy | Grant | 27,000 | $0 | 6/14/2022 | View on chart |
| PBYI | ▼ Sell | Open Market | 25,653 | $72K | 3/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4)
Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.
Puma Biotechnology inducement award under Nasdaq Rule 5635(c)(4). Puma Biotechnology disclosed that it received an inducement award in accordance with Nasdaq Listing Rule 5635(c)(4). The award is intended to assist the company in meeting Nasdaq's continued listing requirements. This filing is a regulatory update that informs investors of the company's compliance actions.